Otsuka, Bristol-Myers Squibb Withdraw Abilify Extension Application In Europe
This article was originally published in PharmAsia News
Japan's fifth-largest drug maker Otsuka Pharmaceutical withdrew its application in Europe for the additional indication of major depressive episodes for its best-selling atypical antipsychotic Abilify (aripiprazole), the European Medicines Agency announced Nov. 19
You may also be interested in...
New claim puts the atypical antipsychotic on par with J&J's Risperdal.
Bristol-Myers Squibb and Japanese partner Otsuka Pharmaceuticals have entered into a two-part deal that extends their 10-year-old collaboration to sell the blockbuster psychiatric drug Abilify (aripiprazole) in the U.S. and also gives Otsuka a presence in oncology in the U.S., Europe and Japan
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).